{"id":"betaferon-betaseron","safety":{"commonSideEffects":[{"rate":"85","effect":"Injection site reactions"},{"rate":"60","effect":"Flu-like symptoms (fever, chills, myalgia)"},{"rate":"70","effect":"Headache"},{"rate":"40","effect":"Fatigue"},{"rate":"25","effect":"Depression"},{"rate":"15","effect":"Elevated liver enzymes"},{"rate":"10","effect":"Leukopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon beta-1b is a recombinant cytokine that enhances natural killer cell activity and increases expression of major histocompatibility complex (MHC) molecules on immune cells. This modulates the immune response in multiple sclerosis by reducing pro-inflammatory cytokine production and decreasing the migration of immune cells across the blood-brain barrier, thereby reducing demyelination and neuroinflammation.","oneSentence":"Betaferon is interferon beta-1b, which activates immune cells and reduces inflammatory responses in the central nervous system to slow disease progression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:28:25.908Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"},{"name":"Secondary progressive multiple sclerosis with active disease"}]},"trialDetails":[{"nctId":"NCT06053749","phase":"","title":"An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-03-20","conditions":"Multiple Sclerosis (MS)","enrollment":4},{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT03535298","phase":"PHASE4","title":"Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2019-01-03","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":800},{"nctId":"NCT04356339","phase":"","title":"US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-11-24","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT02486640","phase":"","title":"Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-09-08","conditions":"Multiple Sclerosis","enrollment":162},{"nctId":"NCT04079088","phase":"PHASE2","title":"Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)","status":"WITHDRAWN","sponsor":"Biogen","startDate":"2021-06-30","conditions":"Relapsing Multiple Sclerosis","enrollment":""},{"nctId":"NCT04356495","phase":"PHASE2, PHASE3","title":"Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2020-07-29","conditions":"Corona Virus Infection, Sars-CoV2","enrollment":412},{"nctId":"NCT00176592","phase":"PHASE4","title":"Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2003-01","conditions":"Multiple Sclerosis","enrollment":75},{"nctId":"NCT00000695","phase":"PHASE1","title":"Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Sarcoma, Kaposi, HIV Infections","enrollment":36},{"nctId":"NCT03808142","phase":"","title":"PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-02-20","conditions":"Multiple Sclerosis","enrollment":79},{"nctId":"NCT01647880","phase":"PHASE2, PHASE3","title":"MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2013-07","conditions":"Multiple Sclerosis","enrollment":15},{"nctId":"NCT01623596","phase":"PHASE4","title":"Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06-08","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":881},{"nctId":"NCT04647695","phase":"PHASE2","title":"IFN-beta 1b and Remdesivir for COVID19","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2020-11-20","conditions":"Covid19","enrollment":100},{"nctId":"NCT03177083","phase":"PHASE4","title":"Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy","status":"COMPLETED","sponsor":"Biogen","startDate":"2017-01-30","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":80},{"nctId":"NCT00436826","phase":"PHASE2","title":"A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2006-11-30","conditions":"Multiple Sclerosis","enrollment":172},{"nctId":"NCT00273364","phase":"PHASE2","title":"Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2005-11-16","conditions":"Multiple Sclerosis","enrollment":110},{"nctId":"NCT04494399","phase":"PHASE2","title":"IFN Beta-1b and Ribavirin for Covid-19","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2020-07-29","conditions":"Covid19","enrollment":96},{"nctId":"NCT04350281","phase":"PHASE2","title":"Double Therapy With IFN-beta 1b and Hydroxychloroquine","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2020-04-09","conditions":"COVID","enrollment":60},{"nctId":"NCT04465695","phase":"PHASE2","title":"Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2020-07-14","conditions":"COVID-19","enrollment":81},{"nctId":"NCT02845843","phase":"PHASE2, PHASE3","title":"MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b","status":"COMPLETED","sponsor":"King Abdullah International Medical Research Center","startDate":"2016-07","conditions":"Middle East Respiratory Syndrome Coronavirus (MERS-CoV)","enrollment":95},{"nctId":"NCT04343768","phase":"PHASE2","title":"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-04-09","conditions":"COVID-19","enrollment":60},{"nctId":"NCT04276688","phase":"PHASE2","title":"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2020-02-10","conditions":"Novel Coronavirus Infection","enrollment":127},{"nctId":"NCT03347370","phase":"","title":"A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2017-11-27","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":626},{"nctId":"NCT02749396","phase":"","title":"EPID Multiple Sclerosis Pregnancy Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-05-02","conditions":"Multiple Sclerosis","enrollment":2089},{"nctId":"NCT03134573","phase":"","title":"Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-09-15","conditions":"Multiple Sclerosis","enrollment":96},{"nctId":"NCT00317564","phase":"","title":"Betaseron Pregnancy Registry","status":"COMPLETED","sponsor":"Syneos Health","startDate":"2006-04","conditions":"Birth Defects, Pregnancy Complications, Multiple Sclerosis","enrollment":113},{"nctId":"NCT00630721","phase":"NA","title":"Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2007-09","conditions":"Multiple Sclerosis","enrollment":56},{"nctId":"NCT02652091","phase":"","title":"Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-05","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":146},{"nctId":"NCT03577977","phase":"","title":"Betaferon Use in Children and Adolescents With Multiple Sclerosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-06-01","conditions":"Multiple Sclerosis","enrollment":70},{"nctId":"NCT03408093","phase":"","title":"Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-02-03","conditions":"Multiple Sclerosis","enrollment":120},{"nctId":"NCT01834586","phase":"PHASE4","title":"Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications","status":"COMPLETED","sponsor":"Brown, Theodore R., M.D., MPH","startDate":"2013-03","conditions":"Multiple Sclerosis","enrollment":30},{"nctId":"NCT01491100","phase":"","title":"Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-04-30","conditions":"Multiple Sclerosis","enrollment":1085},{"nctId":"NCT00623415","phase":"PHASE2","title":"Flupirtine as Oral Treatment in Multiple Sclerosis","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2007-12","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":30},{"nctId":"NCT02391064","phase":"NA","title":"Validation of Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS)","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2015-02-17","conditions":"Multiple Sclerosis","enrollment":421},{"nctId":"NCT01766063","phase":"","title":"Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-12-06","conditions":"Multiple Sclerosis","enrollment":138},{"nctId":"NCT02247310","phase":"","title":"BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-10-20","conditions":"Multiple Sclerosis, Relapsing Remitting","enrollment":498},{"nctId":"NCT02121444","phase":"","title":"BAY86-5046 (Betaseron), Non Interventional Studies","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-06-23","conditions":"Multiple Sclerosis","enrollment":151},{"nctId":"NCT00963833","phase":"","title":"Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-12-17","conditions":"Multiple Sclerosis","enrollment":68},{"nctId":"NCT01049451","phase":"PHASE1","title":"Pulse ACTH vs. MP for MS","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2009-11","conditions":"Multiple Sclerosis","enrollment":23},{"nctId":"NCT01333501","phase":"PHASE4","title":"Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-05","conditions":"Multiple Sclerosis","enrollment":151},{"nctId":"NCT01706055","phase":"","title":"Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-09","conditions":"Multiple Sclerosis","enrollment":629},{"nctId":"NCT01122056","phase":"NA","title":"Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2010-05","conditions":"Multiple Sclerosis","enrollment":128},{"nctId":"NCT01436838","phase":"","title":"China Betaferon Adherence, Coping and Nurse Support Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-03","conditions":"Multiple Sclerosis, Chronic Progressive","enrollment":110},{"nctId":"NCT01403376","phase":"PHASE2","title":"Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-09","conditions":"Multiple Sclerosis","enrollment":128},{"nctId":"NCT02474134","phase":"PHASE1","title":"Comparison Study of PF530 and Betaferon in Healthy Subjects","status":"COMPLETED","sponsor":"Pfenex, Inc","startDate":"2015-03","conditions":"Multiple Sclerosis","enrollment":12},{"nctId":"NCT00370071","phase":"PHASE3","title":"Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-11","conditions":"Multiple Sclerosis","enrollment":39},{"nctId":"NCT00787657","phase":"","title":"Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-06","conditions":"Relapsing Remitting Multiple Sclerosis (RRMS)","enrollment":1723},{"nctId":"NCT00928967","phase":"","title":"Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-05","conditions":"Multiple Sclerosis","enrollment":67},{"nctId":"NCT01795872","phase":"PHASE4","title":"Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-09","conditions":"Multiple Sclerosis","enrollment":278},{"nctId":"NCT00902135","phase":"","title":"Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-05","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":702},{"nctId":"NCT01076595","phase":"","title":"Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-05","conditions":"Multiple Sclerosis","enrollment":73},{"nctId":"NCT01317004","phase":"PHASE4","title":"Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-05","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":61},{"nctId":"NCT00780455","phase":"PHASE4","title":"Rehabilitation Study in MS Patients","status":"TERMINATED","sponsor":"Bayer","startDate":"2008-10","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":4},{"nctId":"NCT00468182","phase":"","title":"Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2007-04","conditions":"Multiple Sclerosis","enrollment":24},{"nctId":"NCT00459667","phase":"PHASE3","title":"BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-05","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":1420},{"nctId":"NCT00439257","phase":"","title":"Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron)","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"","conditions":"Multiple Sclerosis","enrollment":124},{"nctId":"NCT00313976","phase":"PHASE3","title":"Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)","status":"WITHDRAWN","sponsor":"Bayer","startDate":"","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT01354665","phase":"","title":"Depression and Fatigue in MS Patients Treated With Betaferon.","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-05","conditions":"Multiple Sclerosis","enrollment":567},{"nctId":"NCT00206648","phase":"PHASE4","title":"An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-03","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":271},{"nctId":"NCT02234869","phase":"PHASE4","title":"Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy","status":"WITHDRAWN","sponsor":"Biogen","startDate":"2014-10","conditions":"Relapsing Multiple Sclerosis","enrollment":""},{"nctId":"NCT01414816","phase":"","title":"Betaferon® Regulatory Post-Marketing Surveillance","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-04","conditions":"Multiple Sclerosis, Clinically Isolated System","enrollment":355},{"nctId":"NCT00873340","phase":"","title":"Physical Disability in Patients Treated With Betaferon","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-10","conditions":"Multiple Sclerosis","enrollment":83},{"nctId":"NCT00235989","phase":"PHASE2","title":"Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-06","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":63},{"nctId":"NCT01144052","phase":"PHASE4","title":"Natalizumab De-escalation With Interferon Beta-1b","status":"COMPLETED","sponsor":"Claudio Gobbi","startDate":"2010-06","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":19},{"nctId":"NCT01216072","phase":"PHASE4","title":"A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":1053},{"nctId":"NCT01701856","phase":"PHASE4","title":"Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis","status":"TERMINATED","sponsor":"Claudio Gobbi","startDate":"2012-09","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":5},{"nctId":"NCT00490906","phase":"","title":"Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis","status":"COMPLETED","sponsor":"Nancy Hammond, MD","startDate":"2007-06","conditions":"Multiple Sclerosis, Low Bone Density","enrollment":60},{"nctId":"NCT00185211","phase":"PHASE3","title":"BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-08","conditions":"Multiple Sclerosis","enrollment":468},{"nctId":"NCT00317941","phase":"PHASE4","title":"Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-03","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":220},{"nctId":"NCT01464905","phase":"PHASE3","title":"Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)","status":"UNKNOWN","sponsor":"Nuron Biotech Inc.","startDate":"2011-10","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":500},{"nctId":"NCT01404117","phase":"PHASE2","title":"A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability","status":"WITHDRAWN","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-03","conditions":"Relapsing Multiple Sclerosis","enrollment":""},{"nctId":"NCT00428584","phase":"PHASE3","title":"RNF and Betaseron® Tolerability Study","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2006-12","conditions":"Relapsing Remitting Multiple Sclerosis (RRMS)","enrollment":129},{"nctId":"NCT01184833","phase":"","title":"Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-09","conditions":"Multiple Sclerosis","enrollment":852},{"nctId":"NCT00819000","phase":"","title":"Therapy Optimization in Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Teva Neuroscience, Inc.","startDate":"2008-12","conditions":"Multiple Sclerosis","enrollment":2878},{"nctId":"NCT00811395","phase":"PHASE2","title":"Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Multiple Sclerosis","enrollment":182},{"nctId":"NCT01171209","phase":"PHASE2","title":"REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"Melinda Magyari","startDate":"2010-07","conditions":"Multiple Sclerosis","enrollment":10},{"nctId":"NCT00206635","phase":"","title":"Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-01","conditions":"Multiple Sclerosis","enrollment":432},{"nctId":"NCT01233245","phase":"","title":"BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-04","conditions":"Relapsing Remitting MS (RRMS), Secondary Progressive MS (SPMS)","enrollment":1077},{"nctId":"NCT00489489","phase":"PHASE2","title":"Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-05","conditions":"Multiple Sclerosis","enrollment":118},{"nctId":"NCT01235455","phase":"","title":"Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-08","conditions":"Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS)","enrollment":10},{"nctId":"NCT00882453","phase":"","title":"Physical Activity and Fatigue in Early Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-08","conditions":"Multiple Sclerosis","enrollment":1739},{"nctId":"NCT01071694","phase":"","title":"QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2011-01","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":""},{"nctId":"NCT00544037","phase":"","title":"BENEFIT Extension Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-09","conditions":"Multiple Sclerosis","enrollment":283},{"nctId":"NCT01031459","phase":"","title":"Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-01","conditions":"Multiple Sclerosis","enrollment":176},{"nctId":"NCT01432704","phase":"PHASE2, PHASE3","title":"Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"University of Turku","startDate":"2008-03","conditions":"Multiple Sclerosis","enrollment":70},{"nctId":"NCT01111656","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2007-03","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":28},{"nctId":"NCT01339676","phase":"PHASE4","title":"Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)","status":"UNKNOWN","sponsor":"University of Turku","startDate":"2008-03","conditions":"Multiple Sclerosis","enrollment":70},{"nctId":"NCT00461396","phase":"","title":"Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-05","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":104},{"nctId":"NCT01250665","phase":"","title":"Study Comparing Corpus Callosum Atrophy as a Marker of Later Development of Cognitive Impairment in Patients With Multiple Sclerosis","status":"UNKNOWN","sponsor":"Cantonal Hospital of St. Gallen","startDate":"2011-01","conditions":"Multiple Sclerosis, Cognitive Impairment","enrollment":65},{"nctId":"NCT00202995","phase":"PHASE4","title":"Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-07","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":91},{"nctId":"NCT01158183","phase":"","title":"Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-07","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":226},{"nctId":"NCT00893217","phase":"PHASE2","title":"BEYOND Pilot Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-11","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":71},{"nctId":"NCT00942591","phase":"PHASE2","title":"Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2005-05","conditions":"Multiple Sclerosis","enrollment":77},{"nctId":"NCT00099502","phase":"PHASE3","title":"BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-11","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":2244},{"nctId":"NCT00185250","phase":"PHASE2","title":"Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-12","conditions":"Cardiomyopathies, Heart Diseases","enrollment":138},{"nctId":"NCT00298662","phase":"PHASE2","title":"Combination Therapy of Betaseron-Prograf in Multiple Sclerosis","status":"UNKNOWN","sponsor":"Clinique de sclérose en plaques et neuromusculaire de l'Outaouais","startDate":"2003-02","conditions":"Multiple Sclerosis","enrollment":30},{"nctId":"NCT00219908","phase":"PHASE2","title":"Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis","status":"TERMINATED","sponsor":"Rennes University Hospital","startDate":"1999-07","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":124},{"nctId":"NCT00002299","phase":"NA","title":"The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"Cytomegalovirus Retinitis, HIV Infections","enrollment":""},{"nctId":"NCT00002238","phase":"PHASE3","title":"Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen","status":"COMPLETED","sponsor":"Bayer","startDate":"","conditions":"HIV Infections","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ANAPHYLACTIC SHOCK"},{"count":1,"reaction":"MULTIPLE SCLEROSIS"}],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Betaferon/Betaseron","genericName":"Betaferon/Betaseron","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Betaferon is interferon beta-1b, which activates immune cells and reduces inflammatory responses in the central nervous system to slow disease progression. Used for Relapsing-remitting multiple sclerosis, Secondary progressive multiple sclerosis with active disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}